Add to Favorites
Alternative Name
Salivary Gland Fusion Panel
Test Description

The Salivary Gland NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ARID1A, ATF1, CRTC1, CRTC3, DDX3X, ETV6, EWSR1, HMGA2, MAML1, MAML2, MYB, MYBL1, MYH9, NCOA4, NFIB, NTRK1, NTRK2, NTRK3, PLAG1, PRKD1, PRKD2, PRKD3, RET, and USP6.

Clinical Significance

The Salivary Gland NGS Fusion Panel detects gene fusions that may aid in the classification of the disease and selection of patients for available therapies.

Salivary gland tumors have been reported to harbor gene fusions, such as ETV6-NTRK3, MYB-NFIB, EWSR1-ATF1, CRTC1-MAML2, and CRTC3-MAML2. Studies suggest these fusions could be therapeutic targets.

Specimen Requirements
  • FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*
New York Approved
Level of Service
Turnaround Time

21 Days

  1. Inaki R, Abe M, Zong L, et al. Secretory carcinoma - impact of translocation and gene fusions on salivary gland tumor. Chin J Cancer Res. 2017;29(5):379-384. doi:10.21147/j.issn.1000-9604.2017.05.01

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.